KOL Identification

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A top-10 diagnostics player wanted to monitor market development activities and competitive intelligence in the early cancer detection space

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A leader in research and clinical sequencing wanted to assess the market opportunity and key customer segments for an in-house hereditary cancer testing (HCT) solution

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy

A multinational pharmaceutical and diagnostics company was interested in learning more about the U.S. market opportunity for their novel noninvasive prenatal test in development